-
2024-513852-13-00
5
2025-01-20
KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Col
-
2024-514564-13-00
4
2025-01-02
HIV
-
2024-515457-21-00
3
2024-12-30
Non-Hodgkin lymphoma and chronic lymphocytic leukemia
-
2023-508813-18-00
4
2024-12-18
Refractory Focal Onset Epilepsy
-
2023-504022-19-01
5
2024-12-13
Polymyositis or dermatomyositis according to 2017 EULAR / ACR classifi
-
2023-510380-34-00
4
2024-12-10
Diffuse cutaneous systemic sclerosis (dcSSc)
-
2023-509637-39-00
6
2024-11-28
moderate-to-severe psoriasis
-
2024-513441-36-00
4
2024-11-27
MMRp/ MSS colon cancer
-
2024-511838-12-00
3
2024-11-22
Extensive Stage Small Cell Lung Cancer (DeLLphi-308)
-
2024-514917-36-00
5
2024-11-21
Patients with High Risk Neuroblastoma
-
2023-507178-41-00
9
2024-11-07
Hematologic Malignancies or Solid Tumors in Pediatric and Young Adults
-
2023-509912-27-00
5
2024-11-07
Metabolic Dysfunction-Associated Steatotic Liver Disease(MASH) / Nonal
-
2022-502972-22-00
5
2024-10-31
Clostridioides difficile infection.
-
2023-510395-31-00
5
2024-10-30
Metabolic Dysfunction-Associated Steatohepatitis (MASH) with Compensat
-
2023-509340-10-00
5
2024-10-29
Patients with HLA-A2 positive phenotype and metastatic Non-Small Cell
-
2023-508760-29-00
5
2024-10-21
Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
-
2023-509706-30-00
5
2024-10-18
Heart failure (HF)
-
2023-504144-33-01
11
2024-10-17
esophageal cancer
-
2023-508539-30-00
4
2024-10-10
Refractory Focal Onset Epilepsy
-
2023-508338-33-00
5
2024-10-01
Chronic Inflammatory Demyelinating Polyneuropathy
-
2022-501811-14-00
9
2024-09-20
Multiple Myeloma
-
2024-516277-68-00
6
2024-09-19
Crohn's disease
Ulcerative colitis
-
2023-507353-15-00
5
2024-09-10
idiopathic pulmonary fibrosis (IPF)
-
2023-506159-12-00
10
2024-09-06
Generalized Myasthenia Gravis